[Primary HIV drug resistance in a prison population. REPRICOVA-2 Study].
BACKGROUND
Currently, there are few reports on primary human immunodeficiency virus (HIV) drug resistance in the prison population.


METHODS
This is a descriptive, one-day prevalence study to identify HIV drug-resistant mutations in chronically infected treatment-naïve prisoners. Systematic randomized sampling was performed and genotyping was done by automatic sequencing.


RESULTS
A total of 90 patients were studied. Two samples were found to have nucleoside reverse transcriptase inhibitor (NRTI)-resistant mutations, four had non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant mutations and one had protease inhibitor (PI)-resistant mutations.


CONCLUSIONS
There was a low rate of primary resistance in our series. Therefore, resistance testing is not required before prescribing initial antiretroviral therapy in these patients.
García-Guerrero
Julio
J
Centro Penitenciario de Castellón. Spain. garciaj@comcas.es
Herrero
Agustín
A
Bedia
Miguel
M
Araújo
Rosa
R
Castellano
Juan C
JC
D000293:Adolescent; D000328:Adult; D003430:Cross-Sectional Studies; D024882:Drug Resistance, Viral; D005260:Female; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D015995:Prevalence; D011329:Prisoners; D012367:RNA, Viral / Q000097:blood / Q000235:genetics
D012367:RNA, Viral